Obstetrics and Gynecology International / 2010 / Article / Tab 1

Review Article

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer

Table 1

Overview of frequently used histone deacetylase inhibitors that are available for clinical and research purposes.

Substance groupsDerivativesIsotype

HydroxamatesTrichostatin A (TSA)I, II
Suberoylanilide hydroxamic acid (SAHA, vorinostat)I, II, IV
LBH589 (panobinostat)I, II, IV
PCI24781 (CRA-024781)I, IIb
LAQ824I, II
PXD101 (belinostat)I, II, IV
ITF2357I, II
SB939Unknown
JNJ-16241199 (R306465)I
m-carboxycinnamic acid bishydroxamide (CBHA)
Scriptaid
Oxamflatin
Pyroxamide
Cyclic hydroxamic acid containing peptides (CHAPs)

Short chain fatty acidsButyrateI, IIa
ValproateI, IIa
AN-9
OSU-HDAC42

BenzamidesMS-275 (entinostat)1, 2, 3, 9
MGCD01031, 2, 3, 11
Pimelic diphenylamide1, 2, 3
M344
N-acetyldinaline (CI-994)

Cyclic tetrapeptidesApicidineI, II
Trapoxins
HC-toxin
Chlamydocin
Depsipeptide (FR901228 or FK228) (romidepsin)1, 2, 4, 6

Sulfonamide anilidesN-2-aminophenyl-3-[4-(4-methylbenzenesulfonylamino)-phenyl]-2-propenamide

OthersDepudecin
NDH-51
KD5150Pan-HDACI

Class I: HDAC1, -2, -3 and -8; class IIa: HDAC4, -5, -7, and -9; class IIb: HDAC 6, and -10; class III: SIRT1-7; class IV: HDAC11.